11.35 USD
▲+0.37+5.68%
盘后 10.75 +0.09%
2026-08-03
市值
$163.70M
市盈率
—
EPS
-11.41
股息率
—
52 周区间
5.20 – 55.89
成交量
132.44K
Beta
2.10
目标价
20.00
52W 低 5.2052W 高 55.89
价格走势
公司简介
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe d...